Dermatitis (Eczema) – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides an overview of the dermatitis (Eczema) clinical trials scenario. This report provides top-line data relating to the clinical trials on Dermatitis (Eczema). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials (based on several ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database -Pharma – clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news, etc across the globe. Clinical trials database undergoes periodic updates by dynamic process.
Dermatitis (Eczema) clinical trial report consists of 2278 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 225, 283, 645, 490, and 5 respectively. Similarly, the trials with different status compile of completed – 1536, ongoing – 335, planned – 167, suspended – 9, terminated – 81, and withdrawn – 150. Out of 1536 completed trials 777 trials have achieved endpoint.
What are the market dynamics of the global dermatitis (Eczema) therapeutics clinical trials sector?
The number of dermatitis (eczema) clinical trials conducted globally, has increased by over 881% for the period 2016-2020. As of December 2021, out of 1,536 completed trials, 950 trials have results and 777 trials reached endpoints. There were 925 clinical trials in Phase II, of which 128 clinical trials were in progress for the time period 1995-2021. During the same period, there were 335 clinical trials in progress of which 128 trials were in the Phase II study. The trials that were terminated/suspended or withdrawn accounted for 240. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
Asia-Pacific: In the Asia-Pacific region, Japan has the highest number of dermatitis (eczema) clinical trials followed by India, Australia, South Korea, and China.
Europe: Among the European countries, Germany has the highest number of dermatitis (eczema) clinical trials followed by the Netherlands, France, Poland, and the UK.
North America: The US has the highest number of dermatitis (eczema) clinical trials followed by Mexico and Canada.
Middle East and Africa: Iran has the highest number of dermatitis (eczema) clinical trials followed by Israel, South Africa, Morocco, and Egypt.
Central and South America: Brazil has the highest number of dermatitis (eczema) clinical trials followed by Chile, Colombia, Dominican Republic, and Argentina.
G7 countries: Among the G7 (The US, the UK Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of dermatitis (Eczema) to dermatology clinical trials as of December 2021. In total there were 1,502 clinical trials conducted on dermatitis (Eczema), in G7 countries, of these 515 clinical trials were in the US. During the same period, there were 164 clinical trials in progress and 785 trials are completed. The trials that are terminated/suspended or withdrawn accounted for 90.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of dermatitis (Eczema) to dermatology clinical trials as of December 2021. In total there were 449 clinical trials conducted on dermatitis (Eczema), in E7 countries, of these 214 clinical trials were in China. During the same period, there were 88 clinical trials in progress and 200 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 62.
Global dermatitis (Eczema) therapeutics clinical trials sector, by regions
For more regional insights, download a free report sample
Which are the key companies in the global dermatitis (Eczema) therapeutics clinical trials sector?
As of December 2021, Novartis AG sponsored the highest number of dermatitis (eczema) clinical trials followed by Pfizer Inc and Sanofi. Other major companies in the sector are LEO Foundation, GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc, Johnson & Johnson, Eli Lilly and Co, Bayer AG, and Galderma SA.
Global dermatitis (Eczema) therapeutics clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key countries | The US, Germany, Japan, China, Canada, the UK, South Korea, India, Australia and Poland |
Key companies | Novartis AG, Pfizer Inc, Sanofi, LEO Foundation, GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc, Johnson & Johnson, Eli Lilly and Co, Bayer AG, and Galderma SA. |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for unaccomplishment.
- The Report provides enrollment trends for the past five years
- Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
Pfizer Inc
Sanofi
LEO Foundation
GlaxoSmithKline Plc
Regeneron Pharmaceuticals Inc
Bayer AG
Eli Lilly and Co
Johnson & Johnson
Galderma SA
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key countries in the global dermatitis (Eczema) therapeutics clinical trials sector?
Key countries in global dermatitis (Eczema) therapeutics clinical trials sector are the US, Germany, Japan, China, Canada, the UK, South Korea, India, Australia, and Poland.
-
Which are the key companies in the global dermatitis (Eczema) therapeutics clinical trials sector?
Key companies in global dermatitis (Eczema) therapeutics clinical trials sector are Novartis AG, Pfizer Inc, Sanofi, LEO Foundation, GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc, Johnson & Johnson, Eli Lilly and Co, Bayer AG, and Galderma SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.